Patients with diabetes across Pakistan are reportedly facing difficulties finding Apidra insulin, raising concerns among people who depend on the medicine to manage their blood sugar levels.
Apidra, manufactured by Sanofi, contains insulin glulisine, a rapid-acting insulin used to control blood sugar around mealtimes. Patients who rely on it may need medical advice and a suitable alternative if supplies are unavailable. Switching insulin products without professional guidance can affect blood sugar control and create health risks.
The shortage comes amid wider concerns about the availability of essential medicines in Pakistan. According to reports, more than 100 medicines were unavailable in the country, with manufacturers pointing to rising production costs and delays in price adjustments as contributing factors.
However, the exact number of patients affected by the Apidra shortage and its nationwide scale could not be independently confirmed.
The Drug Regulatory Authority of Pakistan (DRAP) allows the public to report medicine shortages through its official website or by emailing [email protected]. Patients should consult their doctors about alternatives rather than stopping insulin or changing doses on their own.
